• 1. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 2. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 3. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 4. Evolution of important glucosinolates in three common Brassica vegetables during their processing into vegetable powder and in vitro gastric digestion
  Nan Fu,Naphaporn Chiewchan,Xiao Dong Chen Food Funct., 2020,11, 211-220
• 5. Ester-mediated peptide formation promoted by deep eutectic solvents: a facile pathway to proto-peptides?
  Chen-Yu Chien,Sheng-Sheng Yu Chem. Commun., 2020,56, 11949-11952

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyridines Imidazopyridines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Imidazopyridines

Professional Introduction to 5-Bromo-3-methylimidazo[1,2-a]pyridine (CAS No. 4926-54-9)

5-Bromo-3-methylimidazo[1,2-a]pyridine, with the chemical formula C₈H₆BBrN₂, is a significant heterocyclic compound that has garnered considerable attention in the field of pharmaceutical and chemical research. This compound, identified by its CAS number CAS No. 4926-54-9, belongs to the imidazopyridine class, a structural motif known for its broad spectrum of biological activities. The presence of both bromine and methyl substituents on the imidazopyridine core enhances its utility as a versatile intermediate in synthetic chemistry and drug discovery.

The< strong>imidazo[1,2-a]pyridine scaffold is a privileged structure in medicinal chemistry due to its ability to interact with various biological targets. It has been extensively studied for its potential applications in the development of small-molecule inhibitors, particularly in oncology and inflammatory diseases. The bromine atom in 5-Bromo-3-methylimidazo[1,2-a]pyridine serves as a reactive handle for further functionalization via cross-coupling reactions, making it a valuable building block for constructing more complex molecules.

In recent years, there has been a surge in research focusing on the development of novel therapeutic agents derived from imidazopyridine derivatives. One notable area of investigation is the exploration of these compounds as kinase inhibitors. Kinases are enzymes that play crucial roles in cell signaling pathways, and their dysregulation is often associated with various diseases, including cancer. Several studies have demonstrated that imidazopyridines can selectively inhibit specific kinases by binding to their active sites. For instance, derivatives of 5-Bromo-3-methylimidazo[1,2-a]pyridine have shown promising activity against tyrosine kinases, which are overexpressed in many cancer cell lines.

The< strong>methyl group at the 3-position of the imidazopyridine ring contributes to the compound's overall pharmacokinetic properties by influencing its solubility and metabolic stability. This modification can be strategically employed to optimize drug-like characteristics, such as oral bioavailability and target engagement. Additionally, the brominated nature of the compound allows for further derivatization through palladium-catalyzed cross-coupling reactions, such as Suzuki-Miyaura and Buchwald-Hartwig couplings. These reactions enable the introduction of diverse functional groups at various positions of the imidazopyridine core, facilitating the synthesis of structurally diverse libraries for high-throughput screening.

Recent advancements in computational chemistry have also played a pivotal role in understanding the interactions between 5-Bromo-3-methylimidazo[1,2-a]pyridine and biological targets. Molecular docking studies have revealed that this compound can bind to specific pockets on protein surfaces, suggesting its potential as an allosteric modulator. Such insights have guided the design of next-generation inhibitors with improved selectivity and potency. Furthermore, virtual screening techniques have been employed to identify novel analogs of 5-Bromo-3-methylimidazo[1,2-a]pyridine that may exhibit enhanced pharmacological properties.

The pharmaceutical industry has recognized the significance of heterocyclic compounds like 5-Bromo-3-methylimidazo[1,2-a]pyridine due to their diverse biological activities and synthetic accessibility. Several clinical trials are currently underway evaluating the efficacy of imidazopyridine-based drugs in treating various therapeutic indications. These trials aim to validate preclinical findings and demonstrate the safety and efficacy of these compounds in human populations. The results from these trials are expected to provide valuable insights into the potential applications of CAS No. 4926-54-9 and its derivatives in clinical practice.

In conclusion, 5-Bromo-3-methylimidazo[1,2-a]pyridine represents a promising scaffold for drug discovery with significant potential in addressing unmet medical needs. Its unique structural features, combined with its reactivity and biological profile, make it an attractive candidate for further exploration. As research continues to uncover new therapeutic applications for imidazopyridines, compounds like CAS No. 4926-54-9 are poised to play a crucial role in shaping the future of medicinal chemistry.

• 5857-47-6(3-Bromo-5-methylimidazo[1,2-a]pyridine)
• 1609400-03-4(5-Bromo-2-methylimidazo1,2-apyridine Hydrochloride)
• 4805-70-3(3-bromo-2-methylimidazo[1,2-a]pyridine)
• 69214-17-1(5-Bromo-2,3-dimethylimidazo[1,2-a]pyridine)
• 947533-74-6(5-bromo-2-tert-butylimidazo[1,2-a]pyridine)
• 74420-43-2(5-Bromo-3-methylimidazo-1,2-apyridine hydrobromide)
• 74420-51-2(5-Bromo-2-methylimidazo[1,2-a]pyridine)
• 881841-53-8((5-Bromoimidazo1,2-apyridin-2-yl)methanol)
• 878197-68-3(5-Bromoimidazo[1,2-a]pyridine-2-carbaldehyde)
• 885275-97-8(5-Bromo-2-chloromethylimidazo1,2-apyridine)